Spots Global Cancer Trial Database for hematologic neoplasms
Every month we try and update this database with for hematologic neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer | NCT00312429 | Hematologic Neo... | Stem Cell Trans... | 18 Years - 70 Years | Duke University | |
| Allogeneic Hematopoietic Stem Cell Transplantation | NCT00750126 | Solid Tumors Hematologic Neo... | Fludarabine, Bu... | - 20 Years | University Hospital, Clermont-Ferrand | |
| Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy | NCT01869218 | Hematologic Neo... | 18 Years - | University of Colorado, Denver | ||
| The ACC Preclinical Research Platform for Precision Oncology | NCT06339541 | Solid Tumor Hematologic Neo... | 14 Years - | Fondazione del Piemonte per l'Oncologia | ||
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL | NCT05902845 | Neoplasms Hematologic Neo... Hematologic Dis... | RD13-02 cell in... | 3 Years - 70 Years | Anhui Provincial Hospital | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Early Palliative Care and Hematological Cancer Patients | NCT03743480 | Hematologic Neo... | early palliativ... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Genomic Testing and Resulting Medical Decisions | NCT03301493 | Cancer of Unkno... Cancer Refracto... Cancer of Stoma... Cancer Head Nec... Cancer of Skin Cancer, Lung Cancer Colorect... Cancer of Esoph... Cancer, Bladder Cancer, Uterus Cancer Cervix Cancer Liver Cancer, Kidney Cancer, Breast Hematologic Neo... | Genomic testing | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation | NCT03680092 | GVHD Hematologic Neo... | Cyclophosphamid... abatacept Methotrexate Tacrolimus | 18 Years - | University of California, San Diego | |
| Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) | NCT03483194 | Hematologic Neo... | Virtual Reality Kalinox | 18 Years - | Weprom | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | NCT02958462 | Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod... | Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | NCT01802879 | Hematologic Neo... | Panobinostat | - | Novartis | |
| Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil | NCT05256537 | Hematologic Neo... | Omission of the... | 18 Years - 75 Years | Cedars-Sinai Medical Center | |
| Comprehensive Frailty Assessment | NCT02033928 | Myeloma, Multip... Paraproteinemia... Hematologic Neo... | 18 Years - | Ohio State University Comprehensive Cancer Center | ||
| Prospective Validation of the OHI Index | NCT05882175 | HLH Hemophagocytic ... Hemophagocytic ... Hematologic Mal... Hematologic Neo... | 18 Years - | Meir Medical Center | ||
| Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | NCT00051311 | Hematologic Neo... | Stem cell trans... Fludarabine Cyclophosphamid... Etoposide Doxorubicin Vincristine Prednisone Methotrexate Cyclosporine Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | NCT00071045 | Neoplasms Hematologic Neo... Healthy Volunte... | 2 Years - 100 Years | National Institutes of Health Clinical Center (CC) | ||
| Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA | NCT04264767 | Cancer Solid Tumor Hematologic Neo... | Blood collectio... | 22 Years - 80 Years | Nucleix Ltd. | |
| Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT | NCT03320915 | Hematologic Neo... | Cholecalciferol | 18 Years - | Seoul National University Hospital | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| UWCCC Molecular Tumor Board Registry | NCT03023202 | Hematologic Neo... Solid Neoplasm | PMMTB (Precisio... | 18 Years - | University of Wisconsin, Madison | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | NCT03908138 | Hematologic Neo... Multiple Myelom... Efficacy Safety | RDD VDD | 18 Years - 65 Years | Shandong Provincial Hospital | |
| Assistance Program for Outpatients Following an Allogeneic Hematopoietic Stem-cell Transplant | NCT04323605 | Hematologic Neo... | Outpatient assi... | 18 Years - | University Hospital, Toulouse | |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | NCT01802879 | Hematologic Neo... | Panobinostat | - | Novartis | |
| Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | NCT00038376 | Lymphoma, T-Cel... Mycosis Fungoid... Hematologic Neo... | Isotretinoin (A... Interferon Alph... | 18 Years - | M.D. Anderson Cancer Center | |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | NCT00997386 | Hematologic Neo... Multiple Myelom... Anemia, Aplasti... Hemoglobinuria,... Myelofibrosis | busulfan, and m... | 18 Years - 75 Years | University of Arizona | |
| RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | NCT03908138 | Hematologic Neo... Multiple Myelom... Efficacy Safety | RDD VDD | 18 Years - 65 Years | Shandong Provincial Hospital | |
| Immunological Profile for Patients Treated With CAR-T Cells | NCT05054231 | Hematologic Neo... | Blood sample co... | 18 Years - | Institut Paoli-Calmettes | |
| Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study | NCT03733249 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | Rimiducid rivogenlecleuce... | 1 Month - 18 Years | Bellicum Pharmaceuticals | |
| Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy | NCT04275154 | Hematologic Neo... | 19 Years - | University of Nebraska | ||
| Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) | NCT04448184 | Hematologic Neo... | Tranexamic Acid | 18 Years - | Ottawa Hospital Research Institute | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| Prophylactic Early PN in HPT/BMT | NCT03083327 | Hematologic Neo... | Parenteral nutr... Pragmatic stand... | 18 Years - | University of Sydney | |
| Intra-bone Cord Blood Transplantation | NCT01332006 | Hematologic Neo... | Intrabone injec... Intra-bone cord... Intra-bone cord... | 18 Years - 65 Years | Università degli Studi di Brescia | |
| Cognitive Training Intervention and Attitudes Towards Genetics | NCT03094026 | Cognitive Impai... Hematologic Neo... Hematopoietic C... | Lumosity Lumosity (waitl... | 21 Years - | University of Alabama at Birmingham | |
| Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation | NCT04691284 | Hematologic Neo... | Blood, urine an... | 18 Years - | National Cancer Institute, Slovakia | |
| Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA | NCT04264767 | Cancer Solid Tumor Hematologic Neo... | Blood collectio... | 22 Years - 80 Years | Nucleix Ltd. | |
| Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | NCT00421213 | Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L... | Darinaparsin | 18 Years - | Alaunos Therapeutics | |
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | NCT02958462 | Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod... | Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Phase I Trial of BAY1251152 for Advanced Blood Cancers | NCT02745743 | Hematologic Neo... | BAY1251152 | 18 Years - | Bayer | |
| Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT | NCT03575767 | Hematologic Neo... Hematopoietic S... Graft Vs Host D... Recurrence | Myeloablative H... | 12 Years - 55 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. | NCT00623870 | Hematologic Neo... | RO5045337 | 18 Years - | Hoffmann-La Roche | |
| Early Palliative Care and Hematological Cancer Patients | NCT03743480 | Hematologic Neo... | early palliativ... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| A Multi-center Investigation of Family Health. | NCT06433349 | Breast Cancer Prostate Cancer Colorectal Canc... Hematologic Neo... Caregivers | Survey and inte... | 18 Years - | Odense University Hospital | |
| Intra-bone Cord Blood Transplantation | NCT01332006 | Hematologic Neo... | Intrabone injec... Intra-bone cord... Intra-bone cord... | 18 Years - 65 Years | Università degli Studi di Brescia | |
| National Marrow Donor Program Long-Term Donor Follow-Up | NCT01362179 | Hematologic Neo... | 18 Years - 60 Years | Center for International Blood and Marrow Transplant Research | ||
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies | NCT02061761 | Hematologic Neo... | BMS-986016 BMS-936558 | 18 Years - | Bristol-Myers Squibb | |
| Prospective Validation of the OHI Index | NCT05882175 | HLH Hemophagocytic ... Hemophagocytic ... Hematologic Mal... Hematologic Neo... | 18 Years - | Meir Medical Center | ||
| Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | NCT00421213 | Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L... | Darinaparsin | 18 Years - | Alaunos Therapeutics | |
| Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies | NCT05895994 | Neoplasms Hematologic Neo... Neoplasms by Si... Hematologic Dis... | RD13-02 cell in... | 3 Years - 70 Years | Wuhan Union Hospital, China | |
| Therapeutic Education in Physical Activity (ETAF) | NCT03403075 | Hematologic Neo... | ETAF Usual care | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients | NCT04303091 | Multiple Myelom... Hematologic Neo... Advanced Cancer | Physical Activi... | 18 Years - | University of Calgary | |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy | NCT02895529 | Hematologic Neo... | Itraconazole Caspofungin | 18 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) | NCT02193880 | Hematologic Neo... Graft-Versus-Ho... | Alpha-beta depl... | 19 Years - 65 Years | University of Alabama at Birmingham | |
| A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy | NCT02895529 | Hematologic Neo... | Itraconazole Caspofungin | 18 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation | NCT00067730 | Sepsis Hematologic Neo... Hematopoietic S... Infection | Drotrecogin Alf... | 18 Years - | Eli Lilly and Company | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies | NCT05672420 | Hematologic Neo... Neutropenia Anemia Thrombocytopeni... Infections Bleeding | umbilical cord ... | 18 Years - 75 Years | Wuhan Union Hospital, China | |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies | NCT02061761 | Hematologic Neo... | BMS-986016 BMS-936558 | 18 Years - | Bristol-Myers Squibb | |
| Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital | NCT05549232 | Hematologic Neo... Burns | Hypoxic Red Blo... | 18 Years - | Hemanext | |
| Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy | NCT04275154 | Hematologic Neo... | 19 Years - | University of Nebraska | ||
| TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia | NCT03136445 | Hematologic Neo... Hemorrhage Hematopoietic S... | Tranexamic acid... Placebo | 18 Years - | NHS Blood and Transplant | |
| Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients | NCT02944045 | Pneumocystis Steroids Immunocompromis... Hematologic Neo... Immunosuppressi... Neoplasms | Methylprednisol... Placebo | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies | NCT00914849 | Hematologic Neo... | AMD3100 Leukopheresis Stem cell trans... | 18 Years - 65 Years | Washington University School of Medicine | |
| Mind-body Medicine for Patients With Malignant Hematological Diseases | NCT03735992 | Hematologic Neo... | Mind-body medic... | 18 Years - | Universität Duisburg-Essen | |
| Trial of Pimasertib in Hematological Malignancies | NCT00957580 | Leukemia, Myelo... Hematologic Neo... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | EMD Serono | |
| Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | NCT00698685 | Leukemia Lymphoma Hodgkin's Disea... Hematologic Neo... Multiple Myelom... Carcinoma, Rena... | Pentostatin Alemtuzumab Allogeneic hema... | 18 Years - 75 Years | University of Arizona | |
| Evaluation of ClearLLab LS Screening Panel | NCT05819762 | Hematologic Mal... Hematologic Neo... Hematologic Dis... | Flow Cytometry | - | Beckman Coulter, Inc. | |
| Early Palliative Care and Hematological Cancer Patients | NCT03743480 | Hematologic Neo... | early palliativ... | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy | NCT05064787 | Lymphoma Lymphoma, B-Cel... Leukemia Multiple Myelom... Mantle Cell Lym... Follicular Lymp... Leukemia, Acute... | Digital Health ... | 18 Years - | Pack Health | |
| Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant | NCT02065869 | Acute Lymphobla... Leukemia, Acute... Lymphoma, Non-H... Myelodysplastic... Primary Immunod... Anemia, Aplasti... Osteopetrosis Hemoglobinopath... Cytopenia Fanconi Anemia Diamond Blackfa... Thalassemia Anemia, Sickle ... | BPX-501 T cells Rimiducid | 1 Month - 18 Years | Bellicum Pharmaceuticals |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
